Welcome to our dedicated page for ARTIVA BIOTHERAPEUTICS SEC filings (Ticker: ARTV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) SEC filings page provides access to the company’s official U.S. Securities and Exchange Commission disclosures, with AI-powered tools to help interpret complex documents. As a clinical-stage biotechnology company focused on NK cell therapies for autoimmune diseases and cancers, Artiva uses filings such as Forms 8-K, 10-Q and 10-K to report material events, financial results and risk factors.
Recent Form 8-K filings highlighted in the available data include current reports on quarterly financial results, initial safety and translational data for AlloNK (AB-101) in autoimmune disease, and corporate matters such as amendments to the 2024 Equity Incentive Plan and equity award exchanges for certain executives. Other 8-Ks reference FDA Fast Track Designation for AlloNK in refractory rheumatoid arthritis and summarize clinical findings from ongoing Phase 1 and 2 trials combining AlloNK with anti-CD20 monoclonal antibodies after cyclophosphamide and fludarabine conditioning.
Through this page, users can review Artiva’s periodic reports, including 10-Q and 10-K filings, to understand research and development expenses, cash, cash equivalents and investments, net losses, and other financial information the company reports. AI-generated summaries can highlight key sections related to AlloNK’s clinical development, the CAR-NK oncology pipeline, the strategic partnership with GC Cell for NK cell manufacturing technology, and the company’s stated risk factors.
Investors can also reference proxy materials and equity plan amendments to see how Artiva structures compensation and equity incentives, as illustrated by the amendment to the 2024 Equity Incentive Plan approved at the 2025 Annual Meeting. Form 4 insider transaction reports, when available, can be used to monitor equity activity by directors and officers. Real-time updates from EDGAR combined with AI explanations help make ARTV’s regulatory record more accessible to readers who want to understand the company’s clinical, financial and governance disclosures in detail.
Form 4 Filing Details: Daniel G. Baker, Director of Artiva Biotherapeutics (ARTV), received a stock option grant for 13,750 shares of common stock on June 24, 2025.
Key transaction details:
- Option exercise price set at $1.61 per share
- Full vesting occurs on the earlier of June 24, 2026, or the 2026 annual stockholder meeting
- Options expire on June 23, 2035
- Transaction reported as a direct ownership
This equity compensation grant appears to be part of the company's director compensation program. The filing was signed by Neha Krishnamohan as attorney-in-fact on June 26, 2025.
Elizabeth L. Hougen, Director at Artiva Biotherapeutics, reported receiving a stock option grant on June 24, 2025. The derivative securities transaction involved:
- Grant of 13,750 stock options to purchase common stock
- Exercise price set at $1.61 per share
- Options will vest fully on the earlier of June 24, 2026, or the date of the 2026 annual stockholder meeting
- Options expire on June 23, 2035
This Form 4 filing represents a standard director compensation equity grant. The options were granted with a 1-year cliff vesting schedule, suggesting alignment with the company's annual director service period. The transaction was executed under direct ownership, with the filing made through an attorney-in-fact on June 26, 2025.
Laura Stoppel, Director at Artiva Biotherapeutics (ARTV), received a stock option grant on June 24, 2025. The grant consists of 13,750 options to purchase common stock at an exercise price of $1.61 per share. The options will fully vest on the earlier of June 24, 2026, or the date of the company's 2026 annual stockholder meeting.
Notable disclosure: Under an arrangement with RA Capital Management, Stoppel holds these options for the benefit of multiple funds: R.A. Capital Healthcare Fund, R.A. Capital Nexus Fund, Nexus Fund III, and a separately managed account. She must turn over any proceeds from exercise to RA Capital Management to offset advisory fees, and therefore disclaims beneficial ownership of both the options and underlying common stock.
The options have a ten-year term, expiring on June 23, 2035. This Form 4 was filed via attorney-in-fact Neha Krishnamohan on June 26, 2025.
Artiva Biotherapeutics Director Gines Diego Miralles received a stock option grant on June 24, 2025, as reported in this Form 4 filing. The derivative securities transaction details include:
- Grant of 13,750 stock options to purchase common stock
- Exercise price set at $1.61 per share
- Options expire on June 23, 2035
- Full vesting occurs on the earlier of June 24, 2026, or the date of the company's 2026 annual stockholder meeting
The filing was executed by Neha Krishnamohan as attorney-in-fact on June 26, 2025. This transaction represents a standard director compensation equity grant, with Miralles holding direct ownership of these derivative securities.
Director Brian Daniels of Artiva Biotherapeutics was granted stock options on June 24, 2025. The key details of this insider transaction include:
- Received 13,750 stock options to purchase common stock
- Exercise price set at $1.61 per share
- Options will expire on June 23, 2035
- Vesting schedule: 100% vesting on the earlier of June 24, 2026, or the date of the 2026 annual stockholder meeting
This grant appears to be part of the company's director compensation program. The transaction was reported via Form 4 filing and executed through an attorney-in-fact, Neha Krishnamohan. The options represent a new position for the director, as no prior holdings were reported in the filing.